公司介紹

台灣活力生技新藥股份有限公司成立於2017年，總部位於台灣桃園市。研發團隊由中研院分子生物研究所之熟諳學理、經驗豐富的黃昭蓮研究員之團隊為基礎組成。主要技術為模版重複聚合酶連鎖反應 (LAE)，可針對免疫標的建構設計抗原，這種新技術結合受體介導、攝取及有效抗原呈現，可誘導免疫反應針對選定之任何抗原（包括自身抗原）產生抗體。此技術設計的治療型疫苗可大幅增加其開發成功率與縮短開發時程，產生的抗體具高親和力和高專一性。目前公司於桃園中壢工業區設立完成QMS廠，提供生產體外臨床檢驗用抗體。本公司獨創之先進技術加上多年之免疫原設計及抗體純化經驗一定可以確保提供顧客優惠價格。

我們提供契約抗體生產服務，有需要的客戶可經由電子郵件 taivital@taivital.com.tw洽談或詢問服務報價。

公司大事年記

Company Profile

Taivital Biopharmaceutical Co. LTD., established in 2017 and headquartered in Taoyuan City, Taiwan, is a promising biopharmaceutical company. The research and development team is leaded by the well-known and experienced researcher Dr. Jaulang Hwang from the Institute of Molecular Biology, Academia Sinica, Taipei, Taiwan. Our innovative Linear Array Epitope (LAE) technology distinguishes us from all others in immunogen and vaccine design. This new technique combines the use of receptor-mediated uptake and an efficient antigen presentation to allow the induction of immune responses to generate antibodies against any antigen (including self-antigens) with high affinity and high specificity. With this LAE technology it enables us to greatly increase in success rate in vaccine design and shorten the development timeline. At present, the company has completed the construction of a QMS plant in Taoyuan Zhongli Industrial Park to provide the production of antibodies for in vitro clinical diagnosis. State-of-the-art technology combined with years of experience in immunogen design and antibody purification, assures that we deliver superior antibodies and purified protein at affordable prices. We now offer contract service programs such as the antibody production service in our QMS plant facility.
You can order or request quotes for customer service directly via e-mail at taivital@taivital.com.tw.